Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 6/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | MAP4K3 | Q8IVH8 | 2/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10100637 | 0.91 | ALOX5AP (0.40) | EPHX2CHEK2CHEK1 | |
| SCHEMBL10100795 | 0.89 | MAP4K3 (0.35) | CHEK2MAP4K3KCNN4PIK3CA | |
| SCHEMBL10100634 | 0.89 | EPHX2 (0.42) | EPHX2CHEK2CHEK1CYP2A6 | |
| SCHEMBL10100793 | 0.88 | KCNN4 (0.38) | MAP4K3KCNN4 | |
| SCHEMBL10100796 | 0.86 | MKNK1 (0.42) | CHEK2MAP4K3KCNN4 | |
| SCHEMBL10100794 | 0.86 | EPHX2 (0.38) | EPHX2CHEK2CHEK1CYP2A6 | |
| SCHEMBL10100791 | 0.85 | FYN (0.39) | MAP4K3KCNN4PIK3CA | |
| SCHEMBL10100705 | 0.85 | LRRK2 (0.41) | MAP4K3 | |
| SCHEMBL10100635 | 0.85 | EPHX2 (0.38) | EPHX2CHEK2CHEK1CYP2A6 | |
| SCHEMBL10100642 | 0.81 | MAP4K3 (0.36) | MAP4K3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518938-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165333-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | EPHX2 2778/4885CHEK2 109/4885CHEK1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.